SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cemtrex, Inc. engages in the provision of solutions in the technology industry. It operates through the following segments: Security, Industrial Services, and Cemtrex Corporate. The Security segment provides end-to-end security solutions to meet corporate, industrial, and governmental security challenges. The Industrial Services segment offers single-source expertise and services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly to diversified customers. The Cemtrex Corporate segment refers to the holding company of the other two segments. The company was founded on April 27, 1998 and is headquartered in Hauppauge, NY.

Cemtrex Inc.

Cemtrex ($CETX) is trending due to a massive premarket surge and multiple trading halts, sparking high volatility. Community chatter revolves around a potential short squeeze reminiscent of $SMX and predictions of continued upward momentum, with some suggesting extremely high price targets. The stock's nano float and recent acquisition news are also fueling the discussion.

Treasure Global, Inc. engages in the provision of payment solutions. The firm created an online-to-offline (O2O) e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs. It operates through the ZCITY Platform and Customized Software Development Service segments. The company was founded by Kok Pin Tan on March 20, 2020 and is headquartered in New York, NY.

Treasure Global Inc

Treasure Global is trending due to a recent revenue target update and chatter around its low float, sparking comparisons to other high-flying stocks like $SMX. Community members are actively discussing the potential for a significant short squeeze, citing high borrow rates and limited share availability. Some investors believe the stock could reach new highs, while others caution about the risks associated with low-float stocks and potential dilution.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences is trending after reporting positive early-stage clinical data for its obesity drug, showing fat loss without muscle loss. The community is discussing the implications of these results, with some speculating about a potential buyout and others pointing out similarities to GLP-1 drugs. Overall sentiment is optimistic, though some caution against over-enthusiasm due to the early stage of the data.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending as investors debate the impact of competitor GPCR's data, particularly focusing on the lack of safety data released and potential implications for Viking's market position. Community discussions revolve around potential partnerships or a buyout, with some emphasizing Viking's strong pipeline and advanced stage in development. There is also ongoing speculation about the possibility of VK2809 skipping Phase 3 trials based on new FDA guidance.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending due to its impending inclusion in the S&P 500, driving significant after-hours price movement. While some investors celebrate the milestone and anticipate further gains, others express concerns about the company's fundamentals and accounting practices, suggesting a potential "sell the news" event. Community discussions revolve around whether the stock is overvalued and if a substantial correction is on the horizon.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SUGP is trending as traders discuss its potential for a low-float squeeze, drawing comparisons to recent runners in the same sector like $SMX. The community is analyzing the stock's float and short borrow fee, with some expressing caution due to a recent offering and warrant dilution. Overall, the focus remains on whether it can achieve a similar explosive move based on its low float.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery ($WBD) is trending amid a potential takeover, with Paramount ($PARA) launching a hostile bid, challenging Netflix's ($NFLX) deal and igniting a bidding war. Community discussion revolves around the merits of each offer, regulatory hurdles, and potential outcomes for shareholders. The stock has seen significant gains YTD, fueled by M&A rumors and speculation.

PMGC Holdings, Inc. is a physician-dispensed skincare company, which engages in the research and development of skincare formulations. It is involved in the production and commercialization of topical skincare products that contain its proprietary stem cell-derived Elevai Exosomes. The company was founded by Hatem Abou-Sayed, Braeden William Lichti, and Jordan R. Plews on June 9, 2020 and is headquartered in Newport Beach, CA.

PMGC Holdings Inc

PMGC Holdings Inc.

ELAB is trending due to a premarket surge, fueled by retail trader interest in PMGC Holdings' shift towards biotech and industrial sectors. Community discussions revolve around the stock's low float and potential for a squeeze, while some traders are pointing to possible overextension. The stock's volatility and previous reverse splits are also being discussed.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

GPCR is trending following Phase 2 data highlighting weight loss percentages, though some investors are wary due to the omission of certain safety data in the initial report. The community is actively discussing the tolerability of the drug, particularly regarding liver enzyme elevations and adverse events like vomiting, while also speculating about potential short squeezes and comparisons to competitors like $LLY and $VKTX. Some see it as a potential acquisition target in the competitive GLP-1 space.

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.

Fulcrum Therapeutics Inc

Fulcrum Therapeutics is trending due to positive initial Phase 1b trial results for its sickle cell disease drug, Pociredir, sparking target price hikes. Community discussions focus on the drug's potential efficacy and clean safety profile, especially regarding increased fetal hemoglobin levels. The broader context includes the promising outlook for oral treatments in sickle cell disease and Fulcrum's potential as a leader in the field.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Samantha Vail

Aurinia Beach

Steven Craig

Broc Segura

Skaped

John Doe

Dave

SirGicho

Derek moler

StockTwits for iOS

NervGen Pharma Corp

Sean Beasley

@Lytnup Only thing that really stuck out to me was the fact that Rogers mentioned that they were still in talks with the FDA regarding AA. Let’s see what happens.

Rich

Bryan Roberts

 Only thing that really stuck out to me was the fact that Rogers mentioned that they were still in talks with the FDA regarding AA. Let’s see what happens.

@Lytnup my main takeaways from the second half (I missed the first half). 

-Phase 3 planning is still early. Sites not identified yet. Still building trial framework which will then be used to recruit sites. 
-NervGen identifies as a central nervous system company, not as an SCI company. 
-Marc commented that the “enhanced plasticity” that is seen with NVG291 is why they think the peptide could be applicable to many other CNR conditions.

 my main takeaways from the second half (I missed the first half). 

-Phase 3 planning is still early. Sites not identified yet. Still building trial framework which will then be used to recruit sites. 
-NervGen identifies as a central nervous system company, not as an SCI company. 
-Marc commented that the “enhanced plasticity” that is seen with NVG291 is why they think the peptide could be applicable to many other CNR conditions.

@MetalinMaybach I’ll have to go back and listen to it again, but towards the end the other panelist (not Rodgers) did mention something about regenerating nerves in other areas of the body besides the injured area, and seemed well informed about how NVG 291 might work in MS patients.  

It was good to hear Dr. Rogers reiterate his focus of getting the drug into the patient’s hands as soon as possible, and that breakthrough and accelerated approvals are things that they’re actively talking to the FDA about.  I was surprised that they haven’t selected sites yet for the phase 3 trial starting in six months, and I’m wondering if an up list to Nasdaq is planned before ￼then…… 60 sites is an ambitious goal, and with their small staff, I would think all of their time would be spent ironing out the logistical details they discussed briefly during the call.

Exciting times! Looking forward to what comes next for this very small company!

Christian Mondi

 I’ll have to go back and listen to it again, but towards the end the other panelist (not Rodgers) did mention something about regenerating nerves in other areas of the body besides the injured area, and seemed well informed about how NVG 291 might work in MS patients.  

It was good to hear Dr. Rogers reiterate his focus of getting the drug into the patient’s hands as soon as possible, and that breakthrough and accelerated approvals are things that they’re actively talking to the FDA about.  I was surprised that they haven’t selected sites yet for the phase 3 trial starting in six months, and I’m wondering if an up list to Nasdaq is planned before ￼then…… 60 sites is an ambitious goal, and with their small staff, I would think all of their time would be spent ironing out the logistical details they discussed briefly during the call.

Exciting times! Looking forward to what comes next for this very small company!

@Skaped I too was encouraged by Dr. Rodger’s brief emphasis on the bigger picture (more than just an SCI repair company), and I thought that their repeating of the importance of getting the trial design right to avoid failures that would set back development timelines was likewise encouraging.

Not sure how they will fund / oversee the P3 across 60 sites with the staffing they have now; partnership news with big Pharma  would be quite welcome at this point, but I think they’ve been pretty consistent stating that for SCI they are going to pursue it on their own.

Wait and see - t’is the love / hate dance of investing in development stage biotech…..

 I too was encouraged by Dr. Rodger’s brief emphasis on the bigger picture (more than just an SCI repair company), and I thought that their repeating of the importance of getting the trial design right to avoid failures that would set back development timelines was likewise encouraging.

Not sure how they will fund / oversee the P3 across 60 sites with the staffing they have now; partnership news with big Pharma  would be quite welcome at this point, but I think they’ve been pretty consistent stating that for SCI they are going to pursue it on their own.

Wait and see - t’is the love / hate dance of investing in development stage biotech…..

@Lytnup I wonder if they’re banking on accelerated approval due to the following. Maybe there’s a reason they’re not moving as quickly as we’d hope. 

“Current practice of the U.S. U.S. Food and Drug Administration (FDA), a confirmatory (often Phase 3) trial usually needs to be at least “underway” for a drug to receive Accelerated Approval — though there are limited exceptions.”

 I wonder if they’re banking on accelerated approval due to the following. Maybe there’s a reason they’re not moving as quickly as we’d hope. 

“Current practice of the U.S. U.S. Food and Drug Administration (FDA), a confirmatory (often Phase 3) trial usually needs to be at least “underway” for a drug to receive Accelerated Approval — though there are limited exceptions.”

@MetalinMaybach Dr. Rodgers mentioned his former company (Hemera) a number of times - he and some other partners founded that company that was eventually sold after P2 results, so I am not quite sure how much experience he has working with the FDA on things like Accelerated Approval.  The early Christmas present, of course, would be a PRV, but I am not holding my breath for that.  He did mention that so far the ups and downs at the FDA leadership level had not impacted their interactions, which was also great to hear.

 Dr. Rodgers mentioned his former company (Hemera) a number of times - he and some other partners founded that company that was eventually sold after P2 results, so I am not quite sure how much experience he has working with the FDA on things like Accelerated Approval.  The early Christmas present, of course, would be a PRV, but I am not holding my breath for that.  He did mention that so far the ups and downs at the FDA leadership level had not impacted their interactions, which was also great to hear.